Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pei-Yu Wu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Refining the Phenotypic and Genotypic Spectrum of WDR73 -Related Galloway-Mowat Syndrome

    by Yao-Lun Yang, Hsiu-Fen Lee, Ching-Shiang Chi, Chi-Ren Tsai, Shu-Ning Liu, Pei-Yu Wu

    The aim of this report was to describe the phenotypic and genotypic spectrum of WDR73-related Galloway-Mowat syndrome (GAMOS). This study comprises a case series conducted from January 2016 to October 2024, along with a systematic review of WDR73-related GAMOS. Analysis was performed on demographic data, clinical features, neuroimaging findings, neurodevelopmental outcomes, and WDR73 gene variants of eligible individuals. We studied 64 individuals, including 4 from this case series and 60 from previous literature. The median reported age at disease onset ranged from 2.5 to 6 months. The most prevalent neurologic feature was microcephaly (55/64; 85.9%), followed by cerebellar atrophy (29/34; 85.3%), ocular abnormalities (54/64; 84.4%), axial hypotonia (52/64; 81.3%), and movement disorders (40/64; 62.5%). Proteinuria (37/64; 57.8%) was the leading extraneurologic feature while hiatal hernia (2/64; 3.1%) was the least observed classic feature. All individuals exhibited psychomotor impairment. A total of 18 WDR73 variants were identified, including 4 novel variants from this case series: c.21G > A (p.Trp7Ter), c.76G > A (p.Ala26Thr), c.214A > G (p.Arg72Gly), and c.884-171_c.*591del. Homozygous WDR73 variants were predominant (61/64; 95.3%) while 3 individuals carried compound heterozygous WDR73 variants. WDR73-related GAMOS is an autosomal recessive, infantile-onset neurodevelopmental disorder with multisystem involvement. Recognizing its clinical manifestations prior to genetic testing may help mitigate reproductive risks and facilitate comprehensive, individualized health care.


  • Open Access

    Genotype–phenotype variations in PURA syndrome: Asian and non-Asian perspectives from a systematic review

    by Shu-Ning Liu, Ching-Shiang Chi, Hsiu-Fen Lee, Chi-Ren Tsai, Yao-Lun Yang, Pei-Yu Wu

    Background: The focus of this study was a comparison of the phenotypical and genotypical differences in PURA syndrome among Asian and non-Asian patients. A retrospective cohort study was performed in a single medical center from January 2014 to May 2025 on patients carrying causative genes for PURA syndrome. A systematic search in PubMed, MEDLINE, Web of Science, and Embase covering the period from January 2014 to May 2025 was conducted. Individuals with PURA syndrome were collected and categorized into Asian and non-Asian groups for analysis. Clinical characteristics, imaging findings, and developmental outcomes were compared between the two groups using Chi-squared or Fisher’s exact tests, with a p < 0.05 considered statistically significant. Results: Of 200 individuals enrolled, 44 were Asian and 156 were non-Asian. 80% or more of individuals with PURA syndrome in both groups shared common clinical features of hypotonia and feeding difficulties during the neonatal period. In terms of neurologic symptoms, there were significantly higher rates of pathological startle response (p < 0.01), and lower rates of epilepsy (p < 0.01) and movement disorders (p = 0.035) among Asian populations. For extra-neurologic symptoms, Asian populations showed a higher incidence of cardiac (p = 0.013) and urogenital abnormalities (p < 0.01), with statistical significance. A single patient in the cohort study exhibited second-degree atrioventricular block, which required pacemaker placement. Highly heterogeneous variants were identified with 106 causative variants in 200 individuals, including a novel causative variant, c.42_57del (p.Leu15fs), from our cohort. All individuals with PURA syndrome displayed evident psychomotor impairment during follow-up. Conclusions: PURA syndrome exhibits high phenotypic and genotypic heterogeneity. Increased pathological startle response, reduced epilepsy and movement disorders, and higher rates of cardiac and urogenital abnormalities were observed in the Asian group. Cardiac conduction disorder may prove fatal without timely intervention.


  • Open Access

    Cerebellar atrophy in genetic epileptic encephalopathies: A cohort study and a systematic review

    by Yao-Lun Yang, Hsiu-Fen Lee, Ching-Shiang Chi, Chi-Ren Tsai, Pei-Yu Wu, Shu-Ning Liu


  • Open Access

    Long-Term Outcome of Pediatric Patients with Anti-NMDA Receptor Encephalitis in a Single Center

    by Pei-Yu Wu, Ching-Shiang Chi, Chi-Ren Tsai, Yao-Lun Yang, Hsiu-Fen Lee

    Background: Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is the most common autoimmune encephalitis in children. There is a high probability of recovery if treated promptly. We aimed to analyze the clinical features and long-term outcomes of pediatric patients with anti-NMDA receptor encephalitis. Method: We conducted a retrospective study with definite diagnoses of anti-NMDA receptor encephalitis in 11 children treated in a tertiary referral center between March 2012 and March 2022. Clinical features, ancillary tests, treatment, and outcomes were reviewed. Results: The median age at disease onset was 7.9 years. There were eight females (72.7%) and three males (27.3%). Three (27.3%) patients initially presented with focal and/or generalized seizures and eight (72.7%) with behavioral change. Seven patients (63.6%) revealed normal brain MRI scans. Seven (63.6%) had abnormal EEG results. Ten patients (90.1%) received intravenous immunoglobulin, corticosteroid, and/or plasmapheresis. After a median follow-up duration of 3.5 years, one patient was lost to follow-up at the acute stage, nine (90%) had an mRS ≤ 2, and only one had an mRS of 3. Conclusions: With the early recognition of anti-NMDA receptor encephalitis based on its clinical features and ancillary tests, we were able to treat patients promptly with first-line treatment and achieve favorable neurological outcomes.